Antipsychotic Selection for Women Planning Pregnancy
For women preparing for pregnancy who require antipsychotic treatment, olanzapine, quetiapine, or aripiprazole are the safest options, with these agents showing no significant increase in major congenital malformations after adjustment for confounders. 1
Primary Recommendation
The second-generation antipsychotics (SGAs) olanzapine, quetiapine, and aripiprazole demonstrate the most favorable reproductive safety profiles for preconception planning. These agents show a major malformation risk of approximately 4.5% in exposed individuals versus 3.5% in unexposed individuals, with no significant increase observed after adjustment for confounding variables 1. Multiple recent guidelines from 2025-2026 consistently support these agents as relatively safe options 2.
Agents to Avoid or Use with Caution
Avoid as First-Line:
- Risperidone and paliperidone: Currently not considered first-line agents due to concerns about malformations 3. Some analyses have associated risperidone with a slightly increased risk of cardiac defects 2, though one large recent study did not replicate this signal 1. The evidence remains mixed but warrants caution.
Insufficient Safety Data:
- Clozapine, ziprasidone, lurasidone: Available safety evidence is limited and insufficient for confident use in pregnancy planning 1
Critical Metabolic Monitoring Considerations
While olanzapine and quetiapine are considered relatively safe for structural malformations, they carry important metabolic risks:
- Olanzapine (particularly) and quetiapine (to a lesser degree) increase risk of:
Clinical Action: For women with pre-existing metabolic risk factors (obesity, prediabetes, family history of diabetes), consider aripiprazole as the preferred agent, as it has lower metabolic liability while maintaining favorable reproductive safety.
Preconception Planning Algorithm
If currently stable on olanzapine, quetiapine, or aripiprazole: Continue the effective medication. Do not discontinue or switch solely because of pregnancy planning, as relapse poses greater risk to mother and baby than potential medication effects 3
If currently on risperidone/paliperidone: Consider switching to olanzapine, quetiapine, or aripiprazole before conception if clinically feasible
If treatment-naive: Choose from olanzapine, quetiapine, or aripiprazole based on:
- Metabolic risk profile (favor aripiprazole if high risk)
- Symptom profile and expected efficacy
- Prior treatment response in family members
Establish baseline monitoring before conception:
- Weight, BMI
- Fasting glucose and lipid panel
- Blood pressure
Dosing Considerations
Do not reduce antipsychotic doses simply because of pregnancy planning or pregnancy itself 3. Antipsychotic metabolism may actually increase during pregnancy, potentially leading to subtherapeutic levels and relapse. Exception: clozapine levels may increase by the third trimester. Doses should always be individualized based on clinical response and therapeutic drug monitoring when available.
Monitoring During Pregnancy
- Monthly metabolic monitoring (weight, glucose) is essential, particularly with olanzapine/quetiapine 1
- Consider ultrasound assessment of fetal size in late pregnancy due to large-for-gestational-age risk 1
- Maintain collaborative care between psychiatry, obstetrics, and primary care 3
Important Caveats
Temporary neurodevelopmental effects: Prenatal antipsychotic exposure may be associated with temporary neurodevelopmental delays in infancy, but these typically resolve within the first 1-2 years and are not associated with long-term health or developmental issues 2. This should not deter appropriate treatment.
Monotherapy preferred: Use single-agent therapy whenever possible, as polypharmacy has been associated with increased risk of adverse pregnancy and infant outcomes 2.
The untreated illness risk: Untreated psychotic illness during pregnancy carries substantial risks including poor prenatal care, substance use, suicide, and infanticide risk postpartum. These risks typically outweigh medication-related risks 3.